Biotage has entered into an agreement to acquire Astrea Bioseparations, a high-growth chromatography solutions provider from Gamma Biosciences. The enterprise value for Astrea is approximately 190 million USD, subject to
Nordic Life Science
Pharma news from the Nordic life science industry
Latest news
The two companies are now supplying Ximluci (ranibizumab biosimilar) in England via a National Health Service (NHS) England Framework Agreement. The partners announced in January 2023 that the UK’s Medicines
Ultomiris has been recommended for marketing authorization in the European Union for the treatment of adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive. If authorised, Ultomiris
Alligator Bioscience has announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application, allowing the company to initiate the OPTIMIZE-2 Phase 2
Modus Therapeutics secures access to bridge financing from longstanding investor Karolinska Development. Access to this funding ensures that momentum of clinical development of Modus’ lead asset, sevuparin, will be enhanced
Oncopeptides has received a research grant of 3 million SEK from Sweden’s Innovation Agency (Vinnova), to explore the development of new treatment options for glioblastoma, an aggressive and incurable form
Vakona has been given a capital injection from five investors to help it develop a new drug to treat acne. “This is a significant investment for us, as now we
The Norwegian company has submitted a cash offer to acquire all shares in Swedish Sensidose for approximately 75 million SEK. The offer is recommended by the independent bid committee of
The study describes a novel method to directly extract membrane proteins from cells into lipid Salipro nanoparticles, enabling structure-function analysis using surface plasmon resonance (SPR) and cryo-electron microscopy (cryo-EM) for
LINK Medical has announced the integration of Pharm Assist into the LINK Medical family. “We are very excited to have Pharm Assist integrate with our network of expert teams, especially
Orion and Bayer further expand the global clinical development program for the oral androgen receptor inhibitor (ARi) darolutamide in prostate cancer. The new Phase III clinical study, ARASTEP, will investigate
Clinical trials
Spago Nanomedical has received regulatory approval to initiate a Phase IIa clinical study with its MRI contrast agent SN132D in endometriosis. Patient recruitment has started, and the first patient is
Affibody has announced that data from treatment with izokibep in the open label part (Part A) of a Phase 2b/3 trial in patients with moderate-to-severe Hidradenitis Suppurativa (HS) will be
Targovax has announced that the first patient has been dosed with cancer vaccine TG01 in the combination study with PD-1 checkpoint inhibitor (CPI) balstilimab in mutant RAS pancreatic cancer in
The company has announced that the first patient was dosed in a trial evaluating bemcentinib in combination with the current standard of care, immune checkpoint inhibitor pembrolizumab and doublet chemotherapy,
Calliditas Therapeutics has announced results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon versus placebo in patients with primary IgA nephropathy.
The company has announced the completion of the patient enrollment in the company’s phase 3 clinical study SPARKLE with the lead candidate drug Orviglance. “We are very pleased to have
The company has reported favorable safety and promising early signs of efficacy following an initial analysis of the phase Ib part of the clinical trial TRIFOUR. In collaboration with the
Modus Therapeutics has announced positive top-line data from its lipopolysaccharide (LPS) provocation study, a key step in evaluating the potential of its lead asset, sevuparin, as a treatment for sepsis
The company has announced topline data from BGBC008, a phase 2 trial evaluating its lead compound bemcentinibin combination with MSD’s anti-PD-1 therapy pembrolizumab in 2L+ Non-Small Cell Lung Cancer (NSCLC)
Sustainability
At Orion Pharma’s Fermion plant waste ethanol is used to reduce the nitrogen load in the Baltic Sea. Outside Hanko in Finland, two different plants are located side-by-side. One of
The manifesto, launched by the trade association for the research-based pharmaceutical industry in Sweden (Lif), includes nine commitments that covers the entire value chain of medicines, from research and development
The professorship at the University of Helsinki, which is being established with the support of a fund, is aimed at strengthening sustainable development expertise in pharmacy across the globe. The
IVL Swedish Environmental Research Institute and Simrishamn Municipality have tested a completley new treatment system that has now been added to the Stengården sewage plant in Simrishamn, Sweden. “Removing pharmaceutical
Nordic efforts to prevent pharmaceuticals affecting the environment include Danish management of hospital wastewater and a Swedish large-scale sewage plant for removal of pharmaceutical residues. Wastewater from hospitals can contain